Enfortumab 

Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Enfortumab Vedotin (Padcev) is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody targeting nectin-4 and monomethyl auristatin E (MMAE). Nectin-4 is highly expressed in urothelial carcinoma, and MMAE is a microtubule disruptor. Enfortumab Vedotin binds to nectin-4 and delivers MMAE to the interior of tumor cells, thereby inhibiting the formation of cell microtubules, leading to cell cycle arrest and apoptosis^[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

145440.00

1448664-46-7

Liquid

Colorless to light yellow

[Enfortumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human Nectin-4 His can bind Enfortumab. The EC₅₀ for this effect is 3.846 ng/mL.

• [1]. Challita-Eid PM, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016 May 15;76(10):3003-13.  [Content Brief]

  [2]. O'Donnell PH, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 Sep 1;41(25):4107-4117.  [Content Brief]